- The first atrial fibrillation procedures using its re-introduced partnered magnetic irrigated catheter were successfully performed in Europe last week.
- The catheter received CE Mark approval in the last week of August following its resubmission to European regulators by the Co's partner in July 2008, and these first cases are part of the standard pre-release evaluation.
- Also in July, the Co's partner submitted a PMA Supplement to the U.S. FDA for use of the magnetic catheter in the U.S. with the expectation that U.S. approval would be obtained subsequent to the European CE Mark.

Other headlines for [STXS]

• STXS 11/6/2008 06:19am
  Stereotaxis, Inc. Names Michael P. Kaminsk new CEO, effective January 1, 2009- Mr. Kaminski, 48, joined Stereotaxis in April 2002 as Chief Operating Officer. Prior to coming to Stereotaxis, he spent nearly 20 years more...
  
• STXS 11/6/2008 06:02am
  Stereotaxis, Inc. Reports Q3 -$0.28 v -$0.27e, R $10.6M v $12.6Me- Q3 GM 66% v 67% y/y
  

Healthcare sector headlines

• CUR Today 08:02am
  Neuralstem Inc Collaborates with Hospital in Taiwan to Develop Additional ALS Stem Cell Clinical Trials- The collaboration will focus on Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease) with Dr. more...
  
• SVA Today 08:01am
  Sinovac Biotech Announces share buyback of up to $2M (5.5% of market cap)
  
• PRX Today 08:01am
  Par Pharmaceutical Companies Inc. Announces successful completion of Bioequivalence Studies for Ondansetron Thin Film- The ondansetron thin film product is being developed for the prevention of chemotherapy-induced nausea and more...
  
• CSKI Today 08:01am
  China Sky One Medical, Inc. Names Yu-Bo Hao new CFO- He replaces Yu-kun Zhang, who had served as interim CFO since June, 2008. - Mr. Hao has been employed at China Sky One in various capacities since June, 2008. - From more...
  
• THRX Today 08:01am
  Theravance Inc Announces positive Phase 2b results for LABA, '444 in the Horizon Asthma Development Programme with GSK- The study, which was designed to evaluate the efficacy of five doses of '444 administered more...